- Home
- SSRM vs BLTE Comparison
SSRM vs BLTE Comparison
Compare SSRM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSRM | BLTE |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SSRM | BLTE |
|---|---|---|
| Price | $31.48 | $170.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $32.74 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 4.0M | 135.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.07 | N/A |
| Revenue Next Year | $3.57 | $492.11 |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $49.00 |
| 52 Week High | $33.49 | $200.00 |
Technical Indicators
Market Signals| Indicator | SSRM | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 55.37 |
| Support Level | $21.71 | $167.80 |
| Resistance Level | $33.49 | $174.78 |
| Average True Range (ATR) | 1.78 | 8.24 |
| MACD | 0.54 | 1.31 |
| Stochastic Oscillator | 88.56 | 78.61 |
Price Performance
Historical ComparisonAbout SSRM SSR Mining Inc.
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.